Skip to main content
    N

    NeoGenomics Inc (NEO)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $16.02
    -0.52 (-3.14%)

    Market Cap: $2.07B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    NeoGenomics Inc (NEO) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    NeoGenomics (NEO) trades at 228.9x trailing earnings and 2.6x sales. Its P/S of 2.6x is below its 5-year median of 2.8x. Its forward P/E is 222.2x. The median P/E across 5 similar companies is 20.5x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 3.0% higher over the next year.

    MultipleValue
    P/E (trailing)228.9x
    Forward P/E222.2x
    Price to sales2.6x
    Price to book2.6x
    EV/EBITDA71.3x
    PEG2.1
    FCF yield-1.4%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 21.2% below 3.3x and its P/B is 16.1% below 3.1x.

    MultipleCurrent5-year median10-year median
    P/S2.6x2.8x3.3x
    P/B2.6x1.9x3.1x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 5 of the 10 year ends shown that have a P/E, its P/E ranged from 53.6x in 2016 to 384.6x in 2020. 2020 was the highest of those years.

    Year endPriceP/EP/SP/B
    2025$11.76N/A2.1x1.8x
    2024$16.48N/A3.2x2.3x
    2023$16.18N/A3.4x2.2x
    2022$9.24N/A2.3x1.2x
    2021$34.12N/A8.7x3.8x
    2020$53.84384.6x13.3x8.9x
    2019$29.2594.4x7.4x6.2x
    2018$12.6163.0x4.1x3.8x
    2017$8.8668.2x2.8x3.4x
    2016$8.5753.6x2.7x3.6x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About NEO

    What is NEO's forward P/E ratio?

    NeoGenomics has a forward P/E ratio of 222.2x.

    Is NEO stock overvalued?

    GNG's valuation label for NEO is Overvalued. Its P/E of 228.9x compares with a median of 20.5x across 5 similar companies.

    What is NEO's price to sales ratio?

    NeoGenomics has a price to sales ratio of 2.6x.

    What is NEO's PEG ratio?

    NeoGenomics has a PEG ratio of 2.1.